Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened

Tracy Tang1, Jean Y. Tang2, Dongwei Li1, Mike Reich1, Christopher A. Callahan1, Ling Fu1, Robert L. Yauch1, Frank Wang3, Karen Kotkow4, Kris S. Chang3, Elana Shpall3, Angela Wu3, Lee L. Rubin4, James C. Marsters, Jr.1, Ervin H. Epstein, Jr.3, Ivor Caro1, and Frederic J. de Sauvage1

Abstract

**Purpose:** Inappropriate activation of the Hedgehog (Hh) signaling pathway in skin is critical for the development of basal cell carcinomas (BCC). We have investigated the anti-BCC efficacy of topically-applied CUR61414, an inhibitor of the Hh signal transduction molecule Smoothened.

**Experimental Design:** In preclinical studies, we used a depilatory model to evaluate the ability of topical formulations of CUR61414 to repress Hh responsive cells found at the base of hair follicles in normal skin. We also tested the in vivo effects of topical CUR61414 on murine BCCs developed in 
Pch1<sup>+/−</sup> K14-CreER2 p53<sup>+/−</sup> mice. In a phase I clinical study, we evaluated the safety, tolerability, and efficacy of a multidose regimen of CUR61414 (0.09%, 0.35%, 1.1%, and 3.1%) applied topically to human superficial or nodular BCCs for up to 28 days.

**Results:** In mice, topical CUR61414 significantly inhibited skin Hh signaling, blocked the induction of hair follicle anagen, and shrank existing BCCs. However, we observed no clinical activity of this formulation in human superficial or nodular BCCs in a phase I clinical study.

**Conclusions:** Our data highlight some of the challenges of translating preclinical experience into successful human results for a topical anticancer agent. 

**Introduction**

The Hedgehog (Hh) signaling pathway, which is active during embryonic development (1), is downregulated in most normal adult tissues. However, aberrant activation of Hh signaling due to mutations in genes encoding signaling pathway components underlies most, if not all, human basal cell carcinomas (BCC), whether arising sporadically or in patients with the heritable basal cell nevus (Gorlin) syndrome (2 to 6).

BCCs commonly contain mutations that inactivate the patched 1 (<i>PITCH1</i>) receptor (4) or constitutively activate the Smoothened (SMO) receptor (7, 8). Both have the same functional consequence—ligand-independent, uncontrolled activation of the Hh signaling pathway. Activation of the Hh pathway in nearly all human BCCs (9, 10) is indicated by increased expression of Hh target genes such as the transcription factor, glioma-associated oncogene homolog 1 (GLI1), and <i>PITCH1</i>, thus suggesting that this is a causal event in tumor initiation. Additional confirmation of the importance of this pathway in BCC was provided by studies of genetically engineered mice showing that BCC-like lesions arise following the introduction of similar genetic perturbations (7 and 11 to 14).

This direct link between the observed genetic mutations and the development of BCC lesions suggests that the development of molecules acting at the level of or downstream of SMO could effectively treat various types of BCCs. A proof of concept for the treatment of locally advanced and metastatic BCC has been provided in the clinic with vismodegib (GDC-0449), an orally available Hh pathway inhibitor acting at the level of SMO (15). However, a topical nonsystemic Hh pathway inhibitor could provide an attractive alternative for the treatment of localized BCCs as it could minimize any possible systemic side effects caused by generalized inhibition of Hh signaling. Current treatments for superficial or nodular BCC include surgical excision, electrodessication and curettage, cryosurgery, and topical chemotherapies such as 5-fluorouracil and imiquimod. Scarring following surgical interventions, significant local skin reactions and limited efficacy restrict the use of the existing topical treatments, particularly in nodular...
Translational Relevance

Aberrant activation of the Hedgehog (Hh) signaling pathway is critical for the development of basal cell carcinoma (BCC). Strong antitumor activity was observed in patients with locally advanced and metastatic BCC using GDC-0449, an oral Hh pathway inhibitor (Von Hoff and colleagues, 2009). However, potential toxicities associated with systemic drug exposure are likely to limit the use of these oral formulations to the most aggressive forms of the disease. A topical nonsystemic Hh pathway inhibitor would have a broader applicability for the treatment of superficial or nodular BCCs. We describe here the development of a topically formulated Hh pathway inhibitor for the treatment of localized superficial or nodular BCCs. We used a novel genetically engineered mouse model of BCC (Ptch1+/−/K14-CreER2 p53 fl/fl) and a depilatory model to evaluate drug efficacy. We also report the first attempt to evaluate the activity of our topically formulated Hh pathway inhibitor in man. Our data highlight some of the challenges of translating preclinical experiences into successful human results for a topical antitumor agent.

BCC, and indicate the need for a new well tolerated topical agent with acceptable efficacy.

CUR61414 is a small-molecule member of the amino-proline class of compounds that was identified in a high throughput screen for inhibitors of the Hh signaling pathway (16). Williams and colleagues showed that the potential therapeutic effectiveness of CUR61414 in vitro murine models by using an embryonic Ptch1+/− skin explant assay in the presence of recombinant sonic Hh or adult Ptch1+/− skin with UV-induced microscopic BCCs. Like GDC-0449, CUR61414 acts downstream of the defective receptor PTCH1 through antagonism of SMO (16).

Here we show that a topical formulation of CUR61414 can downregulate Gli1 expression in normal mouse skin in an in vivo depilatory model and can cause significant tumor regression in a genetically engineered model of BCC. In addition, we report the safety, tolerability, and efficacy for a phase I, double-blinded, randomized, placebo-controlled, multicenter study of CUR61414.

Materials and Methods

Murine studies

Depilatory model. Male mice (Charles River Laboratories), 7 to 8 weeks of age, time at which the hair follicles are all in telogen phase, and 25 to 30 g in body weight, were used in the study following 2 days of acclimation. Only animals that appeared to be healthy and that were free of obvious abnormalities were used for the study. Mice, singly housed during study, were shaved on the dorsal shoulder area, a site difficult for the mouse to lick, and then treated with the depilatory Nair (Church & Dwight Co., Inc.; active ingredient: potassium thioglycolate), for 4 minutes before washing off to induce the hair cycle. Four or 5 days later, vehicle or drug-containing cream was applied to the depilated areas (~0.5 cm²). During topical application mice were under anesthesia.

Gene expression analysis by quantitative PCR

Mouse skin and BCC samples were homogenized with a Polytron homogenizer for 30 seconds to 1 minute at speed 6. Total RNA was isolated from the homogenates (Rneasy Fibrous Midi Kit, Qiagen). RNA samples were DNase-treated (Dnase Kit, Invitrogen), and final RNA concentrations were determined at OD260. One hundred nanograms of RNA were used per well in Taqman quantitative qPCR.

Relative mRNA levels were expressed as [2−(Ct gene − Ct value−reference gene Ct value)] × 1,000. The relative Gli1 mRNA levels were calculated based on normalization to the house keeping gene Rpl19.

Ptch1+/−/K14CreER p53 fl/fl mice and in vivo efficacy study

We have used BCC-susceptible, Ptch1+/−/K14Cre-ER2 p53 fl/fl mice as a model for testing small molecule inhibitors of the Hh pathway. These were generated by breeding mice with the K14-Cre-ER transgene (17) and mice with a floxed p53 allele (18) with Ptch1+/− mice (19). Mice were treated at 6 weeks of age with 100 μg/d of tamoxifen administered intraperitoneally for 3 consecutive days and at 8 weeks of age with 4-Gy ionizing radiation (IR). 160 kV, using an X-ray source (RadSource RS2000 irradiator) to induce BCC formation by 5 months of age. CUR61414 (3.5% wt/wt, formulated in a topical aqueous base cream) or placebo base cream was applied topically twice daily to BCCs on the dorsal skin 5 days a week for up to 42 days. A total of 9 mice with 20 tumors (each less than 14 mm diameter) were treated. Two mice had multiple BCCs that were distantly spaced, and thus some BCCs were treated with CUR61414 and others on the same mouse with placebo. Three mice with closely spaced BCCs were treated with CUR61414 only, and 4 mice with tumors were treated with placebo only. In summary, 4 mice with 10 tumors (mean diameter 7.2 mm) were treated with placebo and 5 mice with 10 tumors (mean diameter 7.0 mm) were treated with CUR61414. The largest tumor diameter was measured thrice weekly by calipers. As per IACUC guidelines, mice with tumors exceeding 20 mm in diameter were euthanized.

Immunohistochemistry

Seven placebo-treated and 6 CUR61414-treated BCCs had enough BCC tumor material for immunohistochemistry and Ki67 analysis. Mouse tissues were fixed in 10% buffered formalin, embedded in paraffin, and cut into 5-μm sections. Sections were deparaffinized in xylene and rehydrated through down grading alcohol. Antigen retrieval was carried out in Trilogy solution (Cell Marque) by...
heating in a pressure cooker. Sections were blocked with 3% hydrogen peroxide, Avidin Biotin blocking system, and normal goat serum (Vector Laboratories) prior to incubation with various rabbit anti-mouse polyclonal antibodies [K10 (1:500), K14 and K17 (1:2000; Covance), caspase-3 (1:800; Pharmingen; overnight at 4°C), and Ki67 (1:400; Thermo Scientific; 60 minutes at room temperature)] and control rabbit immunoglobulin (1:250). Biotinylated goat anti-rabbit (Vector Laboratories) was used to detect the primary antibody and was followed by incubation with the Vectastain ABC kit (Vector Laboratories). Sections were visualized with liquid 3,3′-diaminobenzidine (DAB) and substrate chromogen system (Dako) and counterstained with hematoxylin.

Statistical analysis

Nonparametric t tests (Mann–Whitney) were used to compare the difference in median values of Gli1 mRNA levels and ordinal values of Ki67 staining (0:none to <25%, 1: 25% to 50%, 2: 50% to 74%, 3: >75% positivity), respectively. χ² tests were used to determine the difference in percentage of tumors with large cysts. All P values reported are 2-sided. Graphpad Prism and STATA v10 were used for statistical software.

Human studies

In vitro human percutaneous absorption study. This study was conducted using procedures described previously (20). The CUR61414 formulations (prepared by Dow Pharmaceutical Sciences) were comprised of CUR61414 (1% to 4% w/w), benzyl alcohol (0% to 3% w/w), propylene glycol (10.0% w/w), methylparaben (0.15% w/w), propylparaben (0.05% w/w), emulsifying wax (15.0% w/w), 10% NaOH solution (q.s. pH 6.0), and purified water (q.s. to 100). Formulations were spiked with tracer levels of 14C-labeled CUR61414 (Ci/3.2 mg formulation dose) of (14-C)-labeled CUR61414. Percutaneous absorption was evaluated using dermatomed human abdominal skin mounted on Bronaugh flow-through diffusion cells maintained at 32°C. The receptor fluid, PBS, containing 0.1% sodium azide and 1.5% Oleth 20 was continuously pumped under the dermis at a flow rate of 1 mL/h and collected in 6-hour intervals. A single dose (~5 mg formulation/cm²) was applied to the skin. Following 24-hour exposure, formulation residing on the skin surface was removed by wiping with 2 dry cotton swabs. The stratum corneum was removed from the epidermis with a single cellophane tape-strip and dissolved in 4 mL tetrahydrofuran (THF). The remaining epidermis was then physically separated from the dermis and digested separately in 2N KOH. Quantity of radioactivity in the wipes, tape-strip, epidermis, dermis, and receptor fluid samples was determined using liquid scintillation counting techniques. Epidermal and dermal drug deposition as well as drug penetration were statistically evaluated by performing unpaired Student’s t tests (significant differences between formulations are defined with a value of P < 0.05).

Clinical study

A phase I, double-blind randomized, placebo-controlled, multicenter study (conducted at 7 investigational sites in the United States) was designed to evaluate the safety and tolerability of a multidose regimen of CUR61414 topically applied to superficial or nodular BCCs. The study was reviewed and approved at each investigational site by institutional review boards in accordance with clinical guidelines. Patients with a single or multiple superficial or nodular BCC(s) who met the inclusion and exclusion criteria described in Supplemental Materials and Methods were eligible for study participation. All patients provided informed consent.

A single BCC lesion, confirmed by biopsy during screening (carried out by the Principal Investigator or a sub-investigator who was a board-certified dermatologist), was targeted for treatment with the study drug (CUR61414 or placebo). Up to 3 BCCs per patient were biopsied at screening to select a single target BCC for treatment. The biopsy site of the targeted BCC was to be adequately healed (up to 14 days) prior to the initiation of treatment. Other (nontarget) BCCs that may have been present were not treated with the study drug. All treated lesions were completely excised to clear margins after the treatment and observation periods. During all study segments, the evaluating physician assessed safety and the appearance of the BCC lesion and carried out general physical examinations of patients. For the dose-escalation and MTD expansion segments, the BCC was measured and documented by digital photography at screening and on days 1, 8, 15, 22, 28, and 42.

Once the MTD was determined, enrollment began for the PD marker segment. A total of 8 subjects with a biopsy-confirmed nodular BCC were randomized in a 3:1 ratio (CUR61414 to placebo) to receive 3.1% CUR61414 topically applied twice daily [i.e., every 12 hours (±1 hour)] to the target BCC for 3.5 days, with the final (seventh) dose of study drug being applied the morning of day 4. In addition to histopathologic confirmation of the BCC during the screening period, the biopsy sample was also used to determine the pretreatment level of GLI1 expression. Treatment of the BCC consisted of topical application of a continuous thin film of study drug over the entire surface of the target BCC and margins.

Detailed information about the clinical protocol is described in Supplemental Materials and Methods.

Results

Epidermal and dermal drug deposition and penetration in human skin

We first formulated a cream base containing increasing concentrations of CUR61414 (1% to 4% w/w) spiked with tracer levels of 14C-labeled CUR61414 (1.0 μCi/3.2 mg formulation dose) and tested it in an in vitro human abdominal cadaver skin percutaneous absorption assay. Following 24-hour exposure, the quantity of radioactivity in stratum corneum, epidermis, dermis, and receptor fluid
Topical CUR61414 represses epidermis and dermis layers, respectively. 2% to 5% of the applied doses were absorbed in the formulations (Tables 1 and 2). Six to eleven percent and CUR61414 concentration from 1% to 4% in the cream and the skin penetration were enhanced by increasing the samples indicated that both the epidermal drug deposition and the skin penetration were enhanced by increasing the CUR61414 concentration from 1% to 4% in the cream formulations (Tables 1 and 2). Six to eleven percent and 2% to 5% of the applied doses were absorbed in the epidermis and dermis layers, respectively.

**Topical CUR61414 represses Gli1 expression in normal mouse skin in a depilatory model**

To evaluate the ability of topical formulations of CUR61414 to repress Hh responsive cells found at the base of telogen hair follicles in normal skin (21, 22), we established and optimized a depilatory mouse model. Hair follicles in 7-week old C57BL/6 mice are naturally synchronized in telogen phase of the hair follicle cycle (23). The onset of anagen, a process accompanied by Hh signaling activation, does not occur until 12 weeks of age. Chemical depilation with potassium thioglycolate (Nair) disrupts disulfide bonds, thus damaging hair follicles at the deep root sheath (24). This damage activates Hh signaling and induces the telogen hair follicles in 7-week old mice to undergo anagen. The regeneration of hair follicle depends on the reactivation of follicle growth by the proliferation of hair follicle stem cells at the onset of anagen phase, and Hh has been shown to act as an anagen-inducing signal (25, 26). Time course analysis of Gli1 mRNA levels in skin following hair removal by a combination of shaving and Nair application was first carried out to determine the magnitude and duration of Hh pathway activation in response to hair follicle damage (Fig. 1A). Nair-induced depilation significantly elevated Gli1 expression by day 4 (Fig. 1A) and this increase in Gli1 expression was maintained through day 7.

To determine whether CUR61414 can block Hh pathway activation in this model, we first applied 2 doses of cream containing 0.1% to 3.5% CUR61414 (Fig. 1B). Two percent CUR61414 caused maximal repression of Gli1 expression. Furthermore, application of 2% CUR61414 twice daily over 3 days was more effective than once daily application (7-fold vs. 3-fold Gli1 downregulation; Fig. 1C).

**Table 1. Percutaneous absorption of CUR61414 (% of applied dose)**

<table>
<thead>
<tr>
<th>CUR61414, %</th>
<th>Benzyl alcohol, %</th>
<th>Single tapestrip</th>
<th>Epidermis</th>
<th>Dermis</th>
<th>Receptor</th>
<th>Dose recovered</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 0</td>
<td>6.66 ± 2.95</td>
<td>11.35 ± 1.83</td>
<td>4.73 ± 2.65</td>
<td>2.89 ± 0.63</td>
<td>102.84 ± 9.17</td>
<td></td>
</tr>
<tr>
<td>1 1</td>
<td>4.39 ± 1.95</td>
<td>8.38 ± 1.88</td>
<td>7.85 ± 6.27</td>
<td>2.83 ± 0.54</td>
<td>91.26 ± 4.01</td>
<td></td>
</tr>
<tr>
<td>1 2</td>
<td>4.94 ± 2.22</td>
<td>6.79 ± 1.27</td>
<td>2.50 ± 1.43</td>
<td>2.05 ± 0.04</td>
<td>101.55 ± 18.99</td>
<td></td>
</tr>
<tr>
<td>1 3</td>
<td>3.60 ± 0.52</td>
<td>6.62 ± 1.26</td>
<td>1.69 ± 0.88</td>
<td>2.97 ± 1.16</td>
<td>98.98 ± 12.78</td>
<td></td>
</tr>
<tr>
<td>2 0</td>
<td>5.10 ± 0.50</td>
<td>5.57 ± 1.61</td>
<td>2.55 ± 1.33</td>
<td>1.99 ± 0.41</td>
<td>90.05 ± 13.08</td>
<td></td>
</tr>
<tr>
<td>2 1</td>
<td>5.94 ± 1.53</td>
<td>6.28 ± 3.18</td>
<td>2.72 ± 1.37</td>
<td>2.28 ± 0.41</td>
<td>91.86 ± 7.38</td>
<td></td>
</tr>
<tr>
<td>2 2</td>
<td>6.55 ± 2.36</td>
<td>7.11 ± 1.96</td>
<td>2.03 ± 1.46</td>
<td>1.89 ± 0.19</td>
<td>82.86 ± 5.18</td>
<td></td>
</tr>
<tr>
<td>4 0</td>
<td>5.35 ± 1.07</td>
<td>4.25 ± 0.65</td>
<td>1.96 ± 2.66</td>
<td>1.79 ± 0.20</td>
<td>91.44 ± 7.68</td>
<td></td>
</tr>
<tr>
<td>4 1</td>
<td>5.00 ± 0.73</td>
<td>4.91 ± 1.54</td>
<td>1.80 ± 0.90</td>
<td>2.09 ± 0.30</td>
<td>94.58 ± 10.02</td>
<td></td>
</tr>
<tr>
<td>4 2</td>
<td>5.21 ± 2.24</td>
<td>5.64 ± 2.57</td>
<td>1.72 ± 1.35</td>
<td>1.90 ± 0.20</td>
<td>87.87 ± 5.58</td>
<td></td>
</tr>
</tbody>
</table>

*aMean ± SD.*

**Table 2. Percutaneous absorption of CUR61414 (mass, μg)**

<table>
<thead>
<tr>
<th>CUR61414, %</th>
<th>Benzyl alcohol, %</th>
<th>Single tapestrip</th>
<th>Epidermis</th>
<th>Dermis</th>
<th>Receptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 0</td>
<td>2.13 ± 0.94</td>
<td>3.63 ± 0.58</td>
<td>1.51 ± 0.85</td>
<td>0.92 ± 0.20</td>
<td></td>
</tr>
<tr>
<td>1 1</td>
<td>1.62 ± 0.61</td>
<td>2.73 ± 0.57</td>
<td>2.05 ± 1.70</td>
<td>0.91 ± 0.17</td>
<td></td>
</tr>
<tr>
<td>1 2</td>
<td>1.58 ± 0.71</td>
<td>2.17 ± 0.41</td>
<td>0.80 ± 0.46</td>
<td>0.82 ± 0.35</td>
<td></td>
</tr>
<tr>
<td>1 3</td>
<td>1.15 ± 0.17</td>
<td>2.12 ± 0.40</td>
<td>0.54 ± 0.28</td>
<td>0.95 ± 0.37</td>
<td></td>
</tr>
<tr>
<td>2 0</td>
<td>3.26 ± 0.32</td>
<td>3.57 ± 1.03</td>
<td>1.63 ± 0.85</td>
<td>1.27 ± 0.26</td>
<td></td>
</tr>
<tr>
<td>2 1</td>
<td>3.80 ± 0.98</td>
<td>4.02 ± 2.04</td>
<td>1.74 ± 0.88</td>
<td>1.46 ± 0.26</td>
<td></td>
</tr>
<tr>
<td>2 2</td>
<td>4.19 ± 1.51</td>
<td>4.55 ± 1.25</td>
<td>1.30 ± 0.93</td>
<td>1.21 ± 0.12</td>
<td></td>
</tr>
<tr>
<td>4 0</td>
<td>6.85 ± 1.37</td>
<td>5.44 ± 0.83</td>
<td>2.51 ± 3.41</td>
<td>2.30 ± 0.26</td>
<td></td>
</tr>
<tr>
<td>4 1</td>
<td>6.40 ± 0.93</td>
<td>6.28 ± 1.97</td>
<td>2.30 ± 1.16</td>
<td>2.68 ± 0.38</td>
<td></td>
</tr>
<tr>
<td>4 2</td>
<td>6.66 ± 2.87</td>
<td>7.22 ± 3.29</td>
<td>2.20 ± 1.73</td>
<td>2.44 ± 0.26</td>
<td></td>
</tr>
</tbody>
</table>

*aMean ± SD.*
Topical CUR61414 decreases Hh signaling and shrinks murine BCCs

We next tested the in vivo effects of topical CUR61414 on murine BCCs. After treatment with tamoxifen at 6 weeks of age and exposure to 4 Gy of IR at 8 weeks of age, Pch1<sup>1−/−</sup> K14-CreER2 p53<sup>−/−</sup> mice developed multiple visible nodular BCC tumors starting at 5 to 6 months of age (Epstein Laboratory, unpublished data). These murine BCCs histologically resemble nodular human BCCs (Fig. 2A). Like BCCs in Pch1<sup>1−/−</sup> p53<sup>−/−</sup> wild-type mice (11) the tumors have a high proliferation index as measured by expression of Ki67 and express basal cell markers—keratins 14 and 17 (Fig. 2A)—but not suprabasal differentiation markers—keratin 10 (Fig. 2A). These BCC tumors responded dramatically to topically applied CUR61414. While placebo-treated BCCs increased on average by 40% in size (as measured by tumor diameter) and none shrunk during the course of the study, all CUR61414-treated BCCs decreased by an average of 60% (P < 0.0001; Fig. 2B). Two of 10 CUR61414-treated tumors regressed completely, and the others regressed partially (>50% decrease). Decreased tumor size could be detected within as few as 6 days of treatment and was accompanied by a reduction of Gli1 expression in CUR61414-treated BCCs compared to placebo-treated tumors (Fig. 2C). Furthermore, Gli1 mRNA levels were significantly reduced in tumors treated longer with CUR61414 (N = 8, for 21 days) versus placebo (N = 5, for 12 days), P = 0.011 for difference. Tumors from placebo-treated mice were collected earlier (day 12 vs. day 21) because placebo-treated mice were euthanized due to their tumors exceeding the size permitted by Institutional Animal Care and Use Committee (IACUC) guidelines.

Topical application of CUR61414 significantly reduced tumor cell proliferation as measured by Ki67 staining (Fig. 2A; Fig. 2D, P = 0.034) but, unlike in the studies of Williams and colleagues (16), did not induce significant apoptosis as measured by cleaved caspase-3 (data not shown). The lack of apoptosis in our model could be due to the absence of p53, although HhAntag treatment appears to increase apoptosis in Pch1<sup>1−/−</sup> p53<sup>−/−</sup> murine medulloblastomas (27). CUR61414 also caused tumor necrosis (Fig. 2A) and after 30 days of application, prominent differentiation of tumor cells as indicated by the development of large, keratin filled cysts (Fig. 2A). Cysts developed in most (67%) CUR61414-treated BCCs compared to 18% in placebo-treated BCCs (Fig. 2E, P = 0.02), and cysts in both treatment groups expressed abundant keratins 14 and 17, but little keratin 10 (Fig. 2A). These data suggest that CUR61414-induced cysts may be derived from BCC tumor cells or from hair follicles (28) and hence possibly indirectly from follicular stem cells (29). The cells lining the cysts also have low Ki67 staining. Our data suggest that topical CUR61414 reduces murine BCCs by decreasing tumor proliferation as measured by Ki67 and/or inducing follicular differentiation. These encouraging preclinical data suggest that the topical CUR61414 may be useful for the treatment of human BCC.
Figure 2. CUR61414 mouse BCC data. A, representative photos of BCC tumors treated with placebo or CUR61414. CUR61414 treatment leads to BCC regression and cysts or residual microscopic BCCs on histology. Cysts induced by CUR61414 strongly stain for K14 and K17 and have low staining for K10 similar to placebo-treated BCCs. Cells lining cysts also have low Ki67 staining. B, BCC tumors treated with 3.5% CUR61414 wt/wt (N = 10 tumors, 5 mice) versus placebo cream (N = 10 tumors, 4 mice) twice daily, 5 days per week. Mean and SEM (error bars) are shown. C, reduced Gli1 mRNA levels (normalized to Rpl19) in tumors treated with short term CUR61414 (N = 5 tumors) versus placebo (N = 4 tumors) for less than 8 days, \( P = 0.09 \). Tumors were collected 4 hours after the last cream application. Mean and SEM (error bars) are shown. D, reduced Ki67 staining in tumors treated with CUR61414 (N = 7) versus placebo (N = 6); *, \( P = 0.034 \). Ki67 levels were scored from 0 (none) to 3 (high) as detailed in Materials and Methods. E, percentage of tumors with large cysts, 67% of CUR61414-treated tumors (N = 7) develop cysts on histology compared to 0% of placebo-treated BCCs (N = 6); *, \( P = 0.009 \). A high number represents more cysts.
Clinical experience with CUR61414 in human BCCs

A phase 1, double-blind randomized, placebo-controlled, multicenter study (clinical trial ID THA3435g) was initiated to evaluate, as the primary objective, the safety and tolerability of a multidose regimen of CUR61414 (0.09%, 0.35%, 1.1%, and 3.1%) applied topically to human superficial or nodular BCCs for up to 28 days (Fig. 3A). Between May 2005 and June 2006, a total of 42 patients were enrolled from 7 sites within the United States [34 patients in the dose-escalation and maximum tolerated dose (MTD) expansion segments of the study—29 patients were randomized to active study drug and 5 to placebo; 8 patients in the pharmacodynamic (PD) segment—6 randomized to active drug and 2 to placebo]. It has been reported that approximately 90% of sporadic BCCs have alterations at the PTCH1 locus (often loss of the portion of chromosome 9q harbouring PTCH1) and an additional 10% have activating mutations in SMO (2), leading to the activation of the Hh signaling pathway. While it would be informative to confirm the SMO genotype for the patients enrolled in the trial, we were not able to obtain such information due to limited biopsy materials. No serious adverse events (SAE) were reported, even at the highest dose tested of 3.1%. Of the adverse events (AE) reported, the majority were skin-related and of mild severity, with one case of severe skin erythema in a subject treated at the highest dose.

A secondary objective was to assess clinical activity as determined by the percent of tumors with complete clearance (defined by clinical and histopathologic clearance) after 28 days of CUR61414 treatment compared to placebo. All target tumors were excised at day 42. None of the subjects had complete clearance of their target BCC as defined by complete clinical and histopathologic clearance. However 2 subjects had histopathologic clearance with CUR61414—one subject with a nodular BCC treated with 0.35% cream and the other subject with a superficial BCC treated with 3.1% cream.

We conducted a separate PD study in which we analyzed GLI1 mRNA levels in nodular BCCs on 8 patients before and after treatment with CUR61414 twice daily for 3.5 days (Fig. 3B). This treatment failed to reduce GLI1 expression. Similarly, we found no significant changes in gene expression of 3 other Hh transcriptional target genes (GLI2, PTCH1, and PTCH2) further suggesting a lack of Hh pathway modulation (data not shown). Consistent with the qPCR results, isotopic GLI1 and PTCH1 in situ hybridization (ISH) showed no consistent reduction in GLI1 or PTCH1 transcripts following drug treatment (Supplementary Tables 1 and 2), and both GLI1 and PTCH1 transcript levels remained high in the superficial regions of the CUR61414-treated BCC tumors—the regions closer to the site of the topical treatment—and were comparable to the levels detected in the deeper layer of the biopsies (Fig. 3C; Supplementary Tables 1 and 2).

CUR61414 treatment had little or no effect on the proliferation of BCC tumor cells as judged by Ki-67 staining (Supplementary Table 3). Likewise, IHC for cleaved caspase-3 revealed little or no impact of CUR61414 treatment on tumor cell apoptosis (Supplementary Table 4). Similar Ki-67 or cleaved caspase-3 level was observed between superficial and deep portions of tumors with drug treatment. No histological change such as cyst formation was observed in the treatment group.

Discussion

We have found that topical CUR61414 can downregulate Gli1 expression in normal mouse skin in an in vivo dermal implantation model and can cause significant tumor regression in a genetically engineered model of BCC. The development of a mouse depletory model offered a controlled system where we could synchronize the hair cycle and reliably monitor drug-induced changes in Gli1 mRNA levels. We used this model to rapidly screen multiple topical formulations of CUR61414 and to test various dosing regimens with a sufficiently large number of animals per group for statistical analysis.

**Pch1**+/− mice are susceptible to radiation-induced BCC tumor formation following cesium-137 irradiation (11, 30). Combining Pch heterozygosity with keratin 14-specific deletion of p53 accelerates the rate of BCC tumor formation, avoids the early development of medulloblastomas that occurs in Ptch1+/−; p53−/− mice, and allows the generation of multiple viable BCCs that can be treated and monitored readily. We could detect significant reduction in Gli1 transcript levels and tumor growth in BCCs where topical CUR61414 was applied but not on untreated BCCs in the same mouse. PK analysis of drug concentrations in the plasma collected at the end of the study showed negligible levels of systemic drug exposure (data not shown).

Genetically engineered mouse models of cancers offer powerful tools to test the activity of potential therapeutic agents (31). Nonetheless, the strong anti-SMO and anti-BCC efficacy of topical CUR61414 in the mice was inconsistent with its lack of efficacy on human tumors. In contrast to the murine studies, quantitative RT-PCR and isotopic ISH analysis of the human BCC lesions before and after drug treatment showed unchanged Gli1 expression, indicating lack of exposure. Consequently, CUR61414 did not achieve the secondary clinical activity endpoint of the phase 1 study—there was no complete clinical and histopathologic clearance. This disparity contrasts with the similar anti-BCC efficacy of oral celecoxib in mice and humans (32) and indicates that differences between mouse and human in topical efficacy may exceed those of oral agents.

The lack of clinical efficacy and the failure of topical CUR61414 to downregulate GLI1 in human BCCs is likely due to differential potency of the drug on human versus mouse SMO and/or inadequate drug concentrations in the BCCs due to low penetration or rapid clearance. CUR61414 is 7.5 fold more potent on mouse than human SMO at inhibiting Hh signaling activation in vitro GLI-luciferase assays (IC50 of 0.2 μmol/L in murine S12 cells vs. CLINICAL CANCER RESEARCH
Figure 3. CUR61414 clinical data. A, (i) 3 segments were included in this phase I trial. The first was a dose-escalation segment, with 4 dose groups, for a total of 28 subjects (1). It consisted of 4 periods: screening (day -14 to -1), treatment (day 1 to day 28), observation (day 29 to day 42), and follow-up (day 43 to day 56). The second segment was a MTD expansion segment, consisting of the same 4 periods as the dose-escalation (2). The third was a PD marker segment consisting of 3 periods: screening (day -14 to -1), treatment (day 1 to day 4), and follow-up (day 5 to day 18; ref. 3). (ii) Segment 1 is a dose-escalation study (A = active; P = placebo; Tx = treatment). A low dose of 0.09% was chosen as the starting dose, with subsequent escalation to 3 higher doses in a stepwise manner once all subjects in the dose level had been treated for 4 weeks and preliminary assessment of safety data indicated minimal or no toxicity. Concentrations in the higher dose levels were approximately 3 times the prior concentration, with the highest dose being 3.1%. One subject was randomized to receive placebo in each dose level. All 7 subjects within a dose group completed the treatment period (4 weeks) prior to escalation to the next dose. For dose levels 1 to 3, if fewer than 2 subjects (i.e., 1 subject or no subjects) of the 6 actively treated subjects met the criteria for a DLT following assessment of preliminary safety data, then treatment at the next higher dose was initiated. B, summary of the pretreatment and posttreatment GLI1 levels in the 8 patients enrolled in the PD marker segment. In an interim analysis, conducted after 8 patients were treated (2 patients randomized to placebo and 6 patients received study drug), the PD marker was evaluated by quantitative RT-PCR in the BCC lesion twice: prior to treatment and again in the excised lesion 4 to 6 hours following the last of 7 doses on day 4. A paired t test was used to statistically compare pre- versus post-GLI1 levels within each treatment group (placebo and 3.1%) and a 2-sample t test was used to compare the treatment differences between treatment groups. The observed “PD response” that was seen in one subject treated with placebo was likely due to differences in the cellular content of the posttreatment biopsy, as SMO expression was similarly decreased. C, representative images of GLI1 and PTCH1 ISH on posttreatment BCC samples from 2 patients (patients 2 and 3) who received 7 doses of 3.1% CUR61414 topical application. A total of 11 matched pre- and posttreatment skin biopsies from 4 of the 8 PD patients (one placebo- and 3 CUR61414-treated) were found to contain suitable tumor material for immunohistochemical and ISH analyses. GLI1 and PTCH1 levels (brown spots) in the superficial regions of the skin remained high and comparable to those detected in the deeper areas of the skin.
IC_{50} of 1.5 μmol/L in human HEPM cells). This difference in potency could provide a simple explanation for the disparity we observed between mouse and human BCCs. However, when applied at the highest dose of 3.1%, the estimated effective concentration of CUIR61414 at the target site is 75 times in excess of the IC_{50} 112 μmol/L based on 2% percutaneous absorption (Tables 1 and 2). It is therefore likely that CUIR61414 absorption in human BCCs is significantly lower than that in the human abdominal cadaver skin used in the percutaneous absorption.

We have developed other Hh inhibitors that are 10- to 1000-fold more potent than CUIR61414 as measured by IC_{50}. The significant efficacy of an unrelated Hh pathway inhibitor, GDC-0449, delivered orally in patients with locally advanced and metastatic BCCs (15), confirms the scientific validity of the target. In that study, almost all patients (10 of 13) showed 2-fold or more decrease in tumor size at 16 weeks and all patients had high plasma level of the drug (16.8 to 29.7 μmol/L). There was no correlation between drug concentration and the level of GLI1 downregulation as the amount of drug present is saturating. The absence of GLI1 inhibition in the tumors treated with topical CUIR61414 is therefore consistent with the absence of pathway inhibition likely due to a lack of exposure to the drug. New models to test human percutaneous absorption beyond Franz chamber testing will be needed to predict more effectively the clinical outcome in BCC for topically formulated applications.

Disclosure of Potential Conflicts of Interest

F. Wang, K. Kotkow, and L. L. Rubin were employees of Curis, Inc. during this work. T. Tang, D. Li, M. Reich, C. A. Callahan, L. Fu, R. L. Yauch, J. C. Masters Jr, I. Caro, and F. J. de Sauvage are employees of Genentech, Inc., a wholly owned subsidiary of Hoffmann-La Roche. The other authors disclosed no potential conflicts of interest.

Acknowledgments

The authors thank D. Metzger and P. Chambon for their generous donations of the K14-CreERT2 mice and A. Berns for the p53 β mice used in the Epstein laboratory.

Grant Support

This research was supported in part by a generous donation from the Michael J. Rains Family Foundation to the Epstein laboratory. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 20, 2010; revised February 28, 2011; accepted March 7, 2011; published OnlineFirst May 10, 2011.

References


